The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study

Rebecca Dobson1,11*, Malcolm I. Burgess1,2, Melissa Banks1, D. Mark Pritchard3,4, Jiten Vora4, Juan W. Valle5, Christopher Wong1,2, Carrie Chadwick1, Keith George6, Brian Kevill7, Joanne Adaway7, Joy E. S. Ardill8, Alan Anthonys9, Uschi Hofmann10, Graeme J. Poston1, Daniel J. Cuthbertson1,11

1 Neuroendocrine Tumour Group, University Hospital Aintree, Liverpool, Merseyside, United Kingdom, 2 Department of Cardiology, University Hospital Aintree, Liverpool, Merseyside, United Kingdom, 3 Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, Merseyside, United Kingdom, 4 Neuroendocrine Tumour Group, Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom, 5 Manchester Academic Health Sciences Centre, Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom, 6 Research Institute for Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, Merseyside, United Kingdom, 7 Department of Clinical Chemistry, University Hospital of South Manchester, Wythenshawe, Manchester, United Kingdom, 8 Regional Peptide Laboratory, Kelvin Building, Royal Victoria Hospital, Belfast, United Kingdom, 9 Medical Oncology, CRUK Clinical Cancer Centre, St James University Hospital, Leeds, Yorkshire, United Kingdom, 10 Medical Oncology, Huddersfield Royal Infirmary, Lindley, Huddersfield, Yorkshire, United Kingdom, 11 Department of Obesity and Endocrinology, University of Liverpool, Liverpool, Merseyside, United Kingdom

Abstract

Purpose: Metastatic neuroendocrine tumors secrete serotonin and other vasoactive substances that are responsible for carcinoid syndrome and carcinoid heart disease. We sought to evaluate the discriminatory utility of diagnostic biomarkers in determining the presence and severity of carcinoid heart disease in patients with metastatic neuroendocrine tumors.

Patients and methods: A cross-sectional study of patients with neuroendocrine tumors with documented liver metastases and/or carcinoid syndrome between April 2009–October 2012 in 5 tertiary referral centers. Serum was analyzed for Chromogranin A, Chromogranin B and N-terminal pro Brain Natriuretic Peptide (NT-proBNP). Plasma was analyzed for Neurokinin A and 5-Hydroxyindoleacetic acid (5HIAA). Echocardiography was used to determine the presence and severity of carcinoid heart disease. Non-parametric receiver operating characteristic curves were constructed for biomarkers, and the area under the curve determined. The severity of cardiac involvement was correlated with the concentration of each biomarker.

Results: A total of 187 patients were identified of whom 37 (20%) had carcinoid heart disease. Significantly higher median values of all biomarkers were found in the patients with cardiac involvement. NT-proBNP and plasma 5HIAA had the highest areas under the curve for the prediction of carcinoid heart disease [NT-proBNP 0.82 (95% confidence interval 0.74–0.90, p<0.0001) and 5HIAA 0.85 (95% confidence interval 0.78–0.92, p<0.0001)]. NT-proBNP was moderately correlated (r = 0.48, p<0.001) whereas plasma 5HIAA was only weakly correlated (r = 0.34, p<0.001) with the echocardiographic severity score.

Conclusion: NT-proBNP and plasma 5HIAA are both sensitive and specific biomarkers for the presence of carcinoid heart disease whereas only NT-proBNP is moderately correlated with disease severity.

Introduction

Metastatic mid-gut neuroendocrine tumors (NETs) secrete serotonin and a variety of other vasoactive substances that are responsible not only for the characteristic carcinoid syndrome, but also for the significant long-term complication of carcinoid heart disease.

The pathophysiology of carcinoid heart disease has been elucidated from human and animal studies with increased plasma concentrations of serotonin strongly implicated from several lines of evidence. The specific serotonin re-uptake inhibitors fenfluramine and dexfenfluramine, used as appetite-suppressant drugs, and the ergot alkaloids, ergotamine and methysergide, used in the treatment of migraine, are known to cause valvular fibrosis [1,2]. Secondly, in an in vivo rodent model of carcinoid syndrome, in which there are significant increases in plasma serotonin, mice exhibited fibrotic cardiac valvular disease, which was abrogated by
somatostatin analogues [3]. Other mechanisms are also thought to contribute to the pathophysiology of the disease, with activin A [4] and connective tissue growth factor [5] both associated with the development of carcinoid heart disease. Carcinoid heart disease is characterized by thickening of the tricuspid and pulmonary valves, resulting in regurgitation and/or stenosis of the affected valve [1]. Any or all of the cardiac valves can be affected, with tricuspid regurgitation being the most frequently observed pathology. Involvement of the left sided valves is mainly seen in patients with patent foramen ovale or bronchial carcinoid [6].

Detecting the presence of carcinoid heart disease is important in determining the most appropriate management strategy, particularly with regard to surgical resection of the primary or metastatic tumor [7]. Carcinoid heart disease also has prognostic significance for long term survival [8]. Screening for cardiac involvement is an integral part of the initial assessment and subsequent surveillance protocol in patients with metastatic NETs. Current European Neuroendocrine Tumor (ENETS) guidelines [9] advocate trans-thoracic echocardiography for all patients with carcinoid syndrome, although the recommended screening interval is not stated. The identification of a sensitive and specific biochemical marker that can predict the presence and severity of carcinoid heart disease may direct more rational use of echocardiographic screening.

Previous studies have identified a variety of biomarkers for carcinoid heart disease. The most useful to date has been N-terminal pro-brain natriuretic peptide (NT-proBNP) which has both diagnostic and prognostic significance for cardiac involvement [10,11]. Bhattacharyya et al [12] and subsequently Korse et al [10], found similar cut-off levels of 260 pg/ml and 280 pg/ml for the detection of carcinoid heart disease in patients with carcinoid syndrome. The concentration of Chromogranin A (CgA), present in the chromogranin granules of neuroendocrine cells, has also been significantly associated with the prevalence of and survival from carcinoid heart disease [10]. Furthermore, Neurokinin A (NkA), a tachykinin that is stored and secreted by midgut NETs, is a strong and independent predictor of premature death in these patients [13]. As progression of carcinoid heart disease is thought to be related to serotonin, it might be expected that plasma serotonin, or one of its metabolites, is a useful biochemical correlate of disease severity. Urinary levels of 5-Hydroxyindoleacetic acid (5HIAA), the main metabolite of serotonin, have been linked with the presence and progression of carcinoid heart disease [14,15] but there is no literature on the utility of plasma 5HIAA, a more practical measure. Furthermore we have found no studies of patients with metastatic NETs that compare the discriminatory ability of a panel of biomarkers in the assessment of the presence and severity of carcinoid heart disease.

The aim of the study was to determine which biomarker was best associated with the presence and severity of carcinoid heart disease in patients with metastatic NETs.

Materials and Methods

Participants

All patients with non-pancreatic NETs who visited the outpatient department of one of five tertiary referral NET centers (University Hospital Aintree NHS Trust, Liverpool, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, The Christie Hospital NHS Foundation Trust, Manchester, St James’s University Hospital, Leeds and Huddersfield Royal Infirmary NHS Foundation Trust, Yorkshire) during the study period of April 2009 - October 2012 were eligible.

The inclusion criteria were diagnosis of a NET, with liver metastases and/or carcinoid syndrome (episodes of cutaneous flushing, diarrhea or wheezing) by a specialist neuroendocrine team and clear visualization of all four valves at echocardiography to enable comprehensive assessment of valve leaflet morphology.
mobility and thickening. The exclusion criteria were prosthetic heart valves or inadequate visualization of valves/poor echocardiographic windows such that an echocardiographic score could not be determined. Liverpool Research Ethics Committee approved the study and all patients gave written informed consent. Diagnosis of a NET was based on histological evidence where available, with characteristic immunostaining for CgA and synaptophysin. Histological grading was based on the Ki67 proliferative index. Where histological evidence was not available the diagnosis was made on the basis of characteristic appearances on cross-sectional imaging (computed tomography and/or magnetic resonance) and functional (111In-Octreotide scan) imaging.

All patient records were reviewed and the following extracted: histological diagnosis, tumor proliferative index, duration of disease, primary tumor site, presence or absence and size of hepatic metastases, presence of carcinoid syndrome, use of proton pump inhibitor therapy (a known confounder of CgA levels) and therapeutic interventions. In addition a questionnaire was used to identify New York Heart Association (NYHA) category.

**Blood Samples and Assays**

Venous (non-fasting) blood samples were taken from each patient at the time of echocardiography. Plasma and serum were separated by centrifugation (3,500 rpm) and stored at −80°C until further analysis.

Serum CgA, upper limit of normal (ULN) 3 ng/ml, [synthetic porcine pancreastatin, Peninsula, CA, USA, comparable to the Cis-Bio and DAKO assays] [16] and Chromogranin B (CgB), ULN 12 ng/ml, [GAWK immunoassay, Cambridge Research Biochemical, Cambridge, UK with an intra-assay variation of 12.3% at 12.4 pmol/l to 6.8% at 134 pmol/l] and a corresponding inter-assay variation of 22 and 11% respectively [17] were measured in 157 patients. Serum NT-proBNP, ULN 146 ng/L [18], [electrochemiluminescence technology on the fully automatic Elecsys® analyzer] with intra-assay precision below 4% and an inter-assay precision below 5% at concentrations above 70 pg/ml (Roche Diagnostics) was measured in 172 patients.

Plasma 5HIAA, ULN 23 ng/ml, [LC-MS/MS method (comparable to that used by Tellez et al [19]) with QuanLynx™ software (Waters, Watford, UK) with an inter-assay coefficient of variation of 2.6–9.8% and a intra-assay variation of 2–4.7%] [20] was measured in 145 patients.

| Table 1. Baseline characteristics of all patients, and carcinoid heart disease status. |
|------------------------------------------|-----------------|----------------|----------------|
| Variable                                | All patients (n = 187) | No carcinoid heart disease (n = 150) | Carcinoid heart disease (n = 37) |
| Demographics                            |                  |                           |                             |
| Age (years) †                           | 67±10            | 66±10                      | 68±12                       |
| Male sex                                | 101 (54%)        | 84 (56%)                   | 17 (44%)                    |
| Body mass index (kg/m²) †               | 25.9±5.0         | 26.6±4.5*                  | 22.1±6.0*                   |
| Clinical Characteristics                |                  |                           |                             |
| Histologically confirmed diagnosis      | 166 (89%)        | 136 (90%)                  | 30 (83%)                    |
| Duration of disease (months) †          | 42 (6–74)        | 47 (28–79)                 | 29 (9–63)                   |
| New NET diagnosis at time of echocardiogram | 32 (17%)        | 23 (15%)                   | 9 (24%)                     |
| Proton pump inhibitor therapy            | 54 (29%)         | 46 (30%)                   | 8 (22%)                     |
| Liver metastases                        | 156 (83%)        | 119 (79%)*                 | 37 (97%)*                   |
| Carcinoid syndrome                      | 120 (64%)        | 95 (63%)                   | 25 (68%)                    |
| Site of primary tumor                   |                  |                           |                             |
| Small bowel                             | 132 (71%)        | 108 (72%)                  | 24 (67%)                    |
| Large bowel                             | 12 (6%)          | 11 (7%)                    | 1 (3%)                      |
| Lung                                    | 5 (3%)           | 5 (3%)                     | 0                           |
| Other                                   | 7 (4%)           | 4 (3%)                     | 3 (8%)                      |
| Unknown                                 | 31 (16%)         | 23 (15%)                   | 8 (22%)                     |
| NYHA Class                              |                  |                           |                             |
| I                                       | 133 (71%)        | 117 (77.5%)*               | 16 (44%)*                   |
| II                                      | 49 (26%)         | 33 (22%)                   | 16 (44%)                    |
| III                                     | 4 (2%)           | 1 (0.5%)                   | 3 (8%)                      |
| IV                                      | 1 (1%)           | 0                          | 1 (3%)                      |
| Therapeutic Intervention                |                  |                           |                             |
| SSA therapy                             | 89 (48%)         | 68 (45%)                   | 21 (58%)                    |
| Small bowel resection                   | 118 (63%)        | 101 (67%)*                 | 17 (47%)*                   |
| Hepatic resection                       | 19 (10%)         | 18 (12%)                   | 1 (3%)                      |
| Mean ± standard deviation.              |                  | Median and interquartile range. |
| p<0.05                                  |                  |                             |

NYHA New York Heart Association.

SSA Somatostatin Analogue.

doi:10.1371/journal.pone.0073679.t001
measured in 160 patients. Plasma NkA, ULN 20 ng/L, (an in-house radioimmunoassay developed by the Regional Regulatory Peptide Laboratory, Royal Victoria Hospital, Belfast with an inter-assay coefficient of variation of 6.4–8.4% and an intra-assay coefficient of variation of 1.6–4.6% [21] was measured in 143 patients. All biochemical measurements were made without

Figure 2. Box plots demonstrating spread of results for all 5 biomarkers.
doi:10.1371/journal.pone.0073679.g002
knowledge of the clinical status of the patient. Due to patient-specific and analytical factors not all patients had every biomarker concentration determined.

Trans-thoracic Echocardiography Image Acquisition

All echocardiograms were performed and analyzed by one of two experienced operators, with the patient positioned in the left lateral position on a reclining couch using a GE Vivid 7 or Vivid Q machine (2.5 MHz phased array transducer, Horten, Norway). Valve anatomy and function were assessed in the parasternal long and short axes, and apical 4 chamber, 2 chamber and long axes.

Figure 3. Receiver operator curves for plasma 5HIAA and NT-proBNP with area under curves (AUC) and 95% confidence intervals presented.

doi:10.1371/journal.pone.0073679.g003

Evaluation included 2 dimensional, M-mode, pulsed and continuous wave Doppler and pulsed-wave tissue Doppler imaging. Video loops were acquired triggered to the ECG (3 cardiac cycles) and saved digitally for subsequent off line analysis (Echopac V9.01, GE, Horten, Norway).

Trans-thoracic Echocardiography Image Analysis and Interpretation

A diagnosis of carcinoid heart disease was decided by the operator based on consensus guidelines [9]. Valve regurgitation and stenosis was quantified according to the American College of Cardiology Guidelines [22]. Tricuspid stenosis was quantified according to the mean gradient across the valve (mild 1–5 mmHg, moderate 5–8 mmHg, severe >8 mmHg). Pulmonary stenosis was quantified according to the maximum gradient across the valve (mild <25 mmHg, moderate 25–50 mmHg and severe >50 mmHg). Right ventricular size and function was assessed according to the American Society of Echocardiography guidelines [23]. This enabled calculation of a previously validated echocardiographic score [12] incorporating assessment of all four cardiac valves. Leaflet thickening, mobility and morphology, valvular regurgitation and stenosis, and right ventricular size and function were graded, with higher scores indicating more severe valvular pathology.

To ensure inter-observer agreement a randomly selected subgroup of 108 echocardiographic studies (57%) were cross-checked by a different observer blinded to the initial echocardiographic score. With a maximum score of 66, scores within 2 points were considered to be concordant. In 98 studies the assigned scores were concordant, in ten there was a discrepancy of >2 points, (mean difference 0.269, see figure 1). Where there was score discordance, a third independent observer analyzed the echocardiographic study, blinded to the other scores. An average of the two most concordant scores was then used for these ten echocardiographic studies.

Recruitment

A target of 200 patients was decided at the outset of the study based upon a conservative estimate of 20% incidence of carcinoid heart disease in our patient population. Two hundred patients would be sufficient to demonstrate that an area under the receiver operating characteristic (ROC) curve of 0.65 was better than chance (0.5) with 80% power and at the 5% significance level (with no correction for multiple comparisons). Target recruitment was also based upon the cumulative total of patients attending each of the tertiary referral centers and the availability of a dedicated Cardiology Research Registrar to recruit and study the patients.

Statistical Analysis

Comparisons between continuous variables in the carcinoid heart disease and the non-carcinoid heart disease group were made using the Mann-Whitney U test, as our data did not satisfy the assumption of equal variances for the two-sample t-test. Categorical variables were compared using Chi-square test, or Fisher’s exact test where cell counts were insufficient. Since relationships between the concentration of each biomarker and echocardiographic score were clearly non-linear, Spearman’s rank correlation coefficient (r) was used. For graphical display of bivariate correlations the natural logarithms of the score and biomarker concentrations were used to aid clarity. Non-parametric ROC curves were constructed to assess the ability of each biomarker to discriminate between those patients with and without a diagnosis of carcinoid heart disease. Multivariable logistic
regression was used to assess whether any combination of assays was able to better discriminate between patients with and without carcinoid heart disease compared with any single assay. The number of candidate variables considered was limited to 4 to satisfy the 10 events per variable rule of thumb (Van Belle, 2002). The final model was obtained using a stepwise model selection procedure based on Akaike’s Information Criterion (AIC). Statistical analyses were performed using Stata/IC 12.0 software (StataCorp LP, College Station, TX, USA). A p value of $0.05$ was considered statistically significant. No correction was made for multiple comparisons.

### Results

#### Patients Recruited

Two hundred and eighteen patients were invited to participate. Thirty-one patients were excluded due to a variety of reasons: inadequate visualisation of all four valves preventing calculation of echocardiographic score (26 patients), presence of prosthetic valves (3 patients), inability to provide informed consent (1 patient), and 1 patient declined the invitation to participate, resulting in a total of 187 patients studied. The baseline characteristics of the patients are shown in Table 1. One hundred and sixty-six patients had a histologically confirmed NET. Of the 121 patients with a Ki67 proliferative index reported: 69 patients had a grade 1 tumor ($\text{Ki67} < 2\%$), 50 patients had grade 2 tumors ($\text{Ki67} 2–20\%$) and 2 patients’ tumors were grade 3 ($\text{Ki67} > 20\%$). Thirty-one patients were newly diagnosed (<3 months since presentation) with a

#### Table 2. Diagnostic accuracy of NT-proBNP & plasma 5HIAA.

| NT-proBNP cut point (ng/L) | Sensitivity | Specificity | Correctly classified | Proportion above cut-point | LR+ | LR− |
|---------------------------|-------------|-------------|----------------------|---------------------------|------|-----|
| 100                       | 88          | 54          | 55%                  | 55%                       | 1.9  | 0.2 |
| 200                       | 74          | 73          | 73%                  | 37%                       | 2.8  | 0.3 |
| 300                       | 67          | 82          | 79%                  | 28%                       | 3.6  | 0.4 |
| 400                       | 61          | 87          | 81%                  | 23%                       | 4.6  | 0.4 |
| 500                       | 50          | 93          | 84%                  | 16%                       | 6.8  | 0.5 |
| 600                       | 42          | 95          | 84%                  | 13%                       | 8.1  | 0.6 |

| SHIAA cut point (ng/ml)  | Sensitivity | Specificity | Correctly classified | Proportion above cut-point | LR+ | LR− |
|--------------------------|-------------|-------------|----------------------|---------------------------|------|-----|
| 50                       | 93          | 45          | 54%                  | 96%                       | 1.7  | 0.1 |
| 100                      | 80          | 68          | 71%                  | 82%                       | 2.5  | 0.3 |
| 150                      | 73          | 80          | 79%                  | 74%                       | 3.7  | 0.3 |
| 200                      | 70          | 85          | 83%                  | 68%                       | 4.8  | 0.4 |
| 250                      | 67          | 87          | 83%                  | 63%                       | 5.1  | 0.4 |
| 300                      | 57          | 88          | 83%                  | 58%                       | 4.9  | 0.5 |
| 350                      | 50          | 92          | 84%                  | 54%                       | 5.9  | 0.5 |

$\text{LR}+$ Positive likelihood ratio.  
$\text{LR}−$ Negative likelihood ratio. 

![Figure 4](https://example.com/figure4.png) 

**Figure 4. Scatter diagram demonstrating correlations of NT-proBNP and plasma SHIAA with the echocardiographic score.** 

*doi:10.1371/journal.pone.0073679.g004*
Predictive Value of Biomarkers for Diagnosis of Carcinoid Heart Disease

Significantly higher median values of all 5 biomarkers were found in the patients with carcinoid heart disease compared to those without, (NT-proBNP 474 vs. 79 ng/L, 5HIAA 353 vs. 57 ng/ml, CgA 16 vs. 7 ng/ml, CgB 13 vs. 8 ng/ml and NkA 27 vs. 16 ng/L, Figure 2). Plasma 5HIAA and NT-proBNP had the greatest areas under the curve (AUC) of 0.85 plasma 5HIAA and 0.82 NT-proBNP, Figure 3. The AUCs for CgA, CgB and NkA were 0.69 (0.57–0.80), 0.77 (0.67–0.88) and 0.72 (0.62–0.82) respectively.

The effect of age, sex and creatinine on NT-proBNP was investigated using a multivariable prediction model. NT-proBNP remained statistically significant whereas age, gender and creatinine did not (p = 0.599, 0.521 and 0.749 respectively). A stepwise model selection method (minimizing Akaike’s Information Criterion) demonstrated that age, gender and creatinine do not offer any additional information to discriminate between patients with and without carcinoid heart disease (univariate p-values of 0.277, 0.300 and 0.822 respectively).

The cut-off points for NT-proBNP and plasma 5HIAA with their respective sensitivities and specificities in our patient cohort are illustrated in table 2. The improvement in discriminatory power by inclusion of additional assays into a final logistic regression model was negligible (less than 5-point change in AIC; direct comparison of full model with plasma 5HIAA yielded p = 0.68). For every 50 ng/l increase in NT-proBNP concentration, the odds of carcinoid heart disease increases by 11% (95% confidence interval 5–17%, p<0.0005) and for every 50 ng/ml increase in plasma 5HIAA the odds of carcinoid heart disease increases by 26% (95 confidence interval 14–39%, p<0.0005).

Correlation between Biomarkers and Echocardiographic Severity Score

There were significant correlations between the echocardiographic severity score and concentrations of all biomarkers except CgA. The score correlated most significantly with NT-proBNP (Spearman r = 0.48; p<0.0001) while for the other biomarkers the correlation coefficients were low: plasma 5HIAA (Spearman r = 0.34; p<0.0001), CgA 0.09 (p = 0.25), CgB 0.29 (p<0.0001) and NkA 0.19 (p = 0.03) (Figure 4).

Discussion

Our study is the first large prospective clinical study of patients with metastatic NETs to compare the discriminatory ability of a panel of biomarkers in the assessment of the presence and severity of carcinoid heart disease. We have demonstrated that the median concentrations of all five biomarkers are significantly higher in patients with carcinoid heart disease; however NT-proBNP and plasma 5HIAA had the greatest discriminatory value in the diagnosis of carcinoid heart disease, with NT-proBNP most closely correlating with its severity. Thus in this panel of biomarkers for use in patients with metastatic NETs, NT-proBNP concentration is the most useful biochemical assay for clinicians regarding the presence and severity of cardiac involvement. This finding is consistent with the most recent ENETS and North American Neuroendocrine Tumor (NANETs) consensus guidelines advocating the use of natriuretic peptides where available [24,25].

The optimum cut-off point for NT-proBNP is determined by the relative importance of the sensitivity and specificity of the test. In this circumstance, sensitivity assumes greater importance than specificity, as it is preferable to perform echocardiography on too many patients, rather than miss a diagnosis of carcinoid heart disease. Unlike the results of Korse et al, we found no incremental benefit in combining NT-proBNP with CgA, although there was minor incremental benefit in combining NT-proBNP and plasma 5HIAA in terms of increasing the diagnostic accuracy of the test. A single variable model was considered to be favorable due to its enhanced ease of use in clinical practice. In our series, the cut-off point for NT-proBNP of 260 pg/ml suggested by Bhattacharya, would have a sensitivity of 69% and a specificity of 80%, meaning that 11 patients with carcinoid heart disease would have escaped detection.

NT-proBNP is released from cardiac myocytes with myocyte stretch being the main stimulus for its synthesis and secretion [18]. Elevated levels reflect increased wall tension and pressure, making its measurement of value in carcinoid heart disease. Our finding of the correlation between the degree of elevation of plasma 5HIAA and the development of carcinoid heart disease gives mechanistic insight into the likely contribution of serotonin to the pathogenesis of cardiac involvement. The use of somatostatin analogues (SSAs) that are known to reduce circulating levels of serotonin may be expected to be protective against the development of carcinoid heart disease and as yet, we were unable to confirm this hypothesis. This negative association likely reflects a treatment bias, in that patients with a greater tumor burden are more likely to require treatment with SSAs. Furthermore 83% of our cohort had liver metastases and 64% had carcinoid syndrome but only 48% received SSAs which may have influenced our findings. Prospective human studies are needed to determine whether SSAs can prevent or decrease severity of carcinoid heart disease, although the anti-proliferative effect of SSAs may result in an increasingly higher proportion of patients with metastatic NETs receiving them.

We found a poor correlation between CgA and the severity of carcinoid heart disease which may be because CgA is falsely elevated.
by proton pump inhibitor (PPI) therapy in healthy individuals [26], and those with NETs [27]. Thirty percent of patients who did not have carcinoid heart disease were taking PPI therapy, which undoubtedly will have influenced the CgA results. CgB is known to regulate cardiomyocyte signalling pathways that mediate hypertrophy and heart failure [28]. Furthermore, decreased CgB is not affected by renal function or PPI therapy [29]. These factors may explain why we found CgB to be more sensitive and specific than CgA for carcinoid heart disease. NkA is a specific marker for tumours of the mid-gut origin, this may have affected the NkA results for our patient cohort.

The distribution of NYHA categories in patients with carcinoid heart disease (88% of patients in categories 1 and 2) demonstrates that the disease is often clinically silent, with no discernable attributable symptoms. This is reflected in the weak correlation of the echocardiographic score with NYHA class. We advocate screening all patients with metastatic NETs to facilitate timely diagnosis and management of carcinoid heart disease, and also to assist with the optimum timing of other therapeutic interventions for NETs, e.g. hepatic resection of metastases [7].

While the strength of our study is the large population of NET patients, carefully characterized prospectively from a multi-modality perspective with a comparison of multiple biomarkers, we acknowledge some limitations. Most significantly, our exclusion of patients in whom it was not possible to visualise all 4 cardiac valves may have led to an underestimate in the prevalence of carcinoid heart disease. Additionally, we currently lack data on the utility or discriminatory ability of these biomarkers in determining the mortality from carcinoid heart disease. Further large, long term prospective studies are required to provide robust evidence of the prognostic role of NT-proBNP in the associated mortality from carcinoid heart disease.

Our findings suggest that NT-proBNP or plasma 5HIAA could direct the use of transthoracic echocardiography in the assessment of patients with metastatic NETs. We propose that all such patients undergo a baseline echocardiogram at diagnosis or initial assessment, and if there is no evidence of cardiac involvement, echocardiography is only repeated in the event of an increase in NT-proBNP. Such an approach would necessitate a proportion of patients without carcinoid heart disease being screened unnecessarily but would successfully identify the vast majority of patients with the disease. We recognise that NT-proBNP is not highly specific and therefore unsuitable for monitoring patients with an elevated NT-proBNP attributable to a different pathology. In this scenario, it is necessary to resort to annual echocardiography. In summary, we have demonstrated that NT-proBNP and plasma 5HIAA are equally useful in determining the diagnosis of carcinoid heart disease. NT-proBNP correlates better with severity of disease and may be superior to determine progression but both biomarkers could be used as part of the routine surveillance protocol in patients with metastatic NETs.

References

1. Howard RJ, Drobac M, Rider WD, Keane TJ, Finlayson J, et al. (1982) Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66: 1059–1065.

2. Bhattacharyya S, Schapira AH, Mikhailidh DP, Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374: 537–535.

3. Jackson LN, Chen LA, Larson SD, Silva SR, Ryhachou PG, et al. (2009) Development and characterization of a novel in vivo model of carcinoid syndrome. Clinical Cancer Research 15: 2747–2755.

4. Bergstuen DS, Edwardsen T, Aakhus S, Ueland T, Oie E, et al. (2010) Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis. Neuroendocrinology 92(5): 168–77.

5. Bergstuen DS, Graving J, Haagaa K, Sahakyan LG, Aakhus S, et al. (2010) Plasma CCNC2/connexine tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer 10: 6.

6. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, et al. (2010) Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRI. Circ Cardiovasc Imaging 3: 103–111.

7. Lillegard JB, Fisher JE, Mckenzie TJ, Que FJ, Farnell MB, et al. (2011) Hepatic Resection for the Carcinoid Syndrome in Patients with Severe Carcinoid Heart Disease. J Am Coll Surg 213: 130–139.

8. Molle J, Connolly HM, Rubin J, Seward JB, Modesto K, et al. (2003) Factors Associated with Progression of Carcinoid Heart Disease. N Engl J Med 348: 1003–1015.

9. Plockinger U, Gustafsson BI, Ivan D, Sopak W, Davar J (2009) ENETs Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours. Echocardiography. Neuroendocrinology 90: 190–193.

10. Korse KM, Taal BF, de Groot CA, Bakker RH, Bonfier JMG (2009) Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumour. J Clin Oncol 27: 4293–4299.

11. Zuetenhorst JM, Korse CM, Bonfier JMG, Bakker RH, Taal BF (2004) Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 90: 2073–2079.

12. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J (2008) Usefulness of N-terminal Pro-Brain Natriuretic Peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 102: 938–942.

13. Turner GB, Johnston BT, McCanne DR, McGinity A, Watson RGP (2006) Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 55: 1586–1591.

14. Zuetenhorst JM, Bonfier JMG, Korse CM, Bakker RH, van Tinteren H, et al. (2003) Carcinoid Heart Disease. Cancer 97: 1609–1615.

15. Deveney W, Kemp WE, Anthony LB, Oates JA, Byrd BF (1998) Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 32: 1017–1022.

16. Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meerman KM, et al. (2012) Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol 76: 831–836.

17. Sekiya K, Ghatri MA, Sajahuddin MJ, Bishop AE, Hamid QA, et al. (1989) Production of GAWK (Chromogranin-B 420-493) from Neuroendocrine Tumours and Its Possible Diagnostic Value. J Clin Invest 83: 1834–1842.

18. Hess G, Runkel S, Zdunek D, Hiltzer W (2005) Reference interval determination for N-terminal-B type natriuretic peptide (NT-proBNP):A study in blood donors. Clin Chim Acta 360: 107–113.

19. Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, Woltering EA (2012) A Single Fasting Plasma 5HIAA Value Correlates With 21-Hour Urinary 5HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumours (NETs). Pancreas 42: 43–410.

20. Miller AG, Brown H, Degg T, Allen K, Krevils BG (2010) Measurement of plasma 3-hydroxyisindole acetic acid by liquid chromatography tandem mass spectrometry - Comparison with HPLC methodology. J Chromatogr B 878: 695–699.

21. Mamikunian P, Ardill JE, O’Dorisio TM, Krutzig SR, Vinik AI, et al. (2011) Validation of Neurokinin A Assays in the United States and Europe. Pancreas 40: 1000–1005.

22. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, et al. (2006) ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Disease.
26. Mouli IH, Dennis A, Koecha W, Asher L, Van Uum SHM (2012) Effect of Short-Term Proton Pump Inhibitor Treatment And Its Discontinuation On Chromogranin A in Healthy Subjects. J Clin Endocrinol Metab 97: E1731–E1735.

27. Korse CM, Muller M, Taal BG (2011) Discontinuation Of Proton Pump Inhibitors During Assessment of Chromogranin A Levels In Patients With Neuroendocrine Tumours. Br J Cancer 105: 1173–1175.

28. Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, et al. (2008) Chromogranin B Regulates Calcium Signaling, Nuclear Factor κB Activity, and Brain Natriuretic Peptide Production in Cardiomyocytes. Circ Res 102: 1230–1238.

29. Stridsberg M, Eriksson B, Fellstrom B, Kristiansson G, Janson ET (2007) Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 139: 80–83.